BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
18776 - Human Photoallergy Test
Not Applicable
Withdrawn
- Conditions
- Sunscreening Agents
- Interventions
- Other: BAY987516Other: Untreated skin
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Bayer
- Registration Number
- NCT02751567
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Phase 1
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Drug: Anetumab ravtansine (BAY94-9343)Drug: Pegylated Liposomal Doxorubicin
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT02751918
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States
18793 - Human Photoallergy Test
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: BAY987517Other: Untreated skin
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT02750488
Human Photoallergy Test
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: Sun screening Sport Lotion, (BAY987516)Other: Untreated skin
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT02750449
EPID Multiple Sclerosis Pregnancy Study
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AGOther: No MSDMDs therapy (control)Drug: Extavia (interferon beta-1b), Novartis Pharma AGDrug: Rebif (interferon beta-1a), Merck Serono Europe LtdDrug: Plegridy (peginterferon beta-1a), Biogen Idec LtdDrug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)Drug: Avonex (interferon beta-1a), Biogen Idec Ltd
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2089
- Registration Number
- NCT02749396
- Locations
- 🇫🇮
Many locations, Multiple Locations, Finland
Human Phototoxicity Test
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: Sunscreen Sport Lotion (BAY987516)Other: Untreated Skin
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT02750475
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: BAY1436032
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 81
- Registration Number
- NCT02746081
Phase I Trial of BAY1251152 for Advanced Blood Cancers
Phase 1
Completed
- Conditions
- Hematologic Neoplasms
- Interventions
- Drug: BAY1251152
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 21
- Registration Number
- NCT02745743
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
Completed
- Conditions
- Venous Thrombosis and Pulmonary Embolism
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 528
- Registration Number
- NCT02742623
18750-Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: Coppertone (BAY987517)
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT02741466
© Copyright 2025. All Rights Reserved by MedPath